Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy

Journal Article · Sun Jul 01 00:00:00 EDT 1984 · J. Nucl. Med.; (United States)

OSTI ID:6668913

Fawwaz, R A; Wang, T S.T.; Srivastava, S C; Rosen, J M; Ferrone, S; Hardy, M A; Alderson, P O

Palladium-109, a beta-emitting radionuclide, was chelated to the monoclonal antibody 225.28S to the high molecular weight antigen associated with human melanoma. Injection of the radiolabeled monoclonal antibody into nude mice bearing human melanoma resulted in significant accumulation of the radiolabel in the tumors: 19% injected dose/g; 38:1 and 61:1 tumor-to-blood ratios at 24 and 48 hr, respectively. The localization of the radiolabeled antibody in liver and kidney also was high, but appreciably lower than that achieved in tumor. These results suggest Pd-109-labeled monoclonal antibody to tumor-associated antigens may have potential applications in tumor immunotherapy.

• Research Organization: Columbia Univ., New York, NY
• OSTI ID: 6668913
• Journal Information: J. Nucl. Med.; (United States), Vol. 25:7
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
BIOLOGICAL ACCUMULATION
TISSUE DISTRIBUTION
PALLADIUM 109
IMMUNOTHERAPY
KIDNEYS
LIVER
MELANOMAS
MICE
RADIOTHERAPY
ANIMALS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DIGESTIVE SYSTEM
DISEASES
DISTRIBUTION
EVEN-ODD NUCLEI
GLANDS
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MAMMALS
MEDICINE
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
PALLADIUM ISOTOPES
RADIOISOTOPES
RADIOLOGY
RODENTS
THERAPY
VERTEBRATES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
550601 - Medicine- Unsealed Radionuclides in Diagnostics